id.osteomyelitis-septic-arthritis.v1PRODUCTION

id.osteomyelitis-septic-arthritis.v1

Acute Osteomyelitis & Septic Arthritis

infectious_diseaseacutesubacuteadultpediatricneonatalgeriatric

Hard-required inputs

0 / 13

Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Bone & joint infection spectrum: acute osteomyelitis (hematogenous — peds metaphyseal AHO + adult vertebral osteomyelitis/discitis; contiguous — post-trauma/surgical/diabetic-foot/decubitus/dental; direct-inoculation — open fracture/plantar puncture) + native septic arthritis (closed-space orthopaedic EMERGENCY — cartilage destruction within hours) + prosthetic-joint infection (biofilm-mediated) × acute (< 2 wk, no sequestrum) vs subacute/chronic (sequestrum, involucrum, sinus tract, Brodie abscess) × pathogen-host band (S. aureus incl MRSA default; Kingella < 4 yr; GBS neonate; gonococcal sexually active; Salmonella sickle-cell; Pseudomonas IVDU/plantar-puncture; Streptococcus) (Berbari IDSA 2015; IDSA/PIDS 2021; Osmon IDSA PJI 2013)

Inputs

Actions

Advance rule

Set

Advance when

BJI phenotype framed (syndrome × route × acuity × pathogen-host band × native/prosthetic)

Patient inputs (17)

age*demographic • CONTEXT

Age stratifies pathogen prior + empiric regimen (Kingella kingae leading in 6-48 mo — β-lactam, intrinsically vancomycin/clindamycin-resistant; GBS + S. aureus + Gram-negative in neonate; gonococcal in sexually active adolescent/adult), Kocher applicability (paediatric hip), and short-course IV-to-oral candidacy (Peltola / IDSA-PIDS 2021)

temperature*vital • CONTEXT

Fever > 38.5 °C is a Kocher predictor and a sepsis-screen component; absence of fever does NOT exclude septic arthritis (immunosuppressed / gonococcal / partially treated)

host_risk_factors*history • CONTEXT

not present

RA, prosthetic joint, recent intra-articular injection/surgery, immunosuppression, diabetes, IVDU, sickle-cell disease, advanced age, prior BJI — raise pre-test probability and shift the pathogen prior (sickle-cell → Salmonella; IVDU/plantar-puncture → Pseudomonas; prosthetic → CoNS/biofilm) (Margaretten JAMA 2007 PMID 17405973)

prosthetic_or_hardware_status*history • CONTEXT

Prosthetic joint or internal fixation present → PJI / implant-associated infection pathway; biofilm-mediated; source-control strategy (DAIR vs 1-/2-stage exchange) + rifampin combination for retained staph hardware (Osmon IDSA PJI 2013)

monoarthritis_features*symptom • ENTRY

Warm, swollen, painful joint with restricted active + passive ROM and effusion → arthrocentesis indication; polyarticular pattern (~ 15-20 %) carries worse prognosis and suggests immunosuppression / RA / disseminated gonococcal (Margaretten JAMA 2007 PMID 17405973)

weight_bearing_status*symptom • ENTRY

Non-weight-bearing / refusal to bear weight is a Kocher predictor of paediatric septic hip and a red flag in any age; pseudoparalysis in a neonate = septic arthritis/osteomyelitis until proven otherwise (Kocher 1999 PMID 10608376; IDSA/PIDS 2021)

symptom_duration_and_route*history • FRAME

not present

Symptom duration (< 2 wk acute vs subacute/chronic with sequestrum) + route (hematogenous vs contiguous vs direct-inoculation) determines source-control aggressiveness, biopsy strategy, and IV-to-oral candidacy (OVIVA Li NEJM 2019 PMID 30699315; Berbari IDSA 2015)

synovial_fluid_analysis*lab • INITIAL_WORKUP

Synovial WBC + differential (> 50,000 /µL PMN-predominant LR+ 7.7; > 100,000 LR+ 28; < 25,000 LR− 0.32 — does NOT exclude in immunosuppressed/gonococcal/prosthetic), Gram stain, culture, crystal microscopy (crystals do not exclude co-existent sepsis) (Margaretten JAMA 2007 PMID 17405973)

blood_cultures*lab • INITIAL_WORKUP

Blood cultures positive in ~ 30-50 % of haematogenous osteomyelitis / septic arthritis — when positive often define the organism and may obviate biopsy; S. aureus bacteraemia → screen for endocarditis (TEE) (Berbari IDSA 2015)

crp_esr_baseline_and_trend*lab • INITIAL_WORKUP

CRP + ESR for diagnosis and the monitoring workhorse; CRP > 20 mg/L is a strong paediatric septic-hip predictor (Caird 2006 PMID 16757758); failure of CRP to fall by ~ day 3-5 despite adequate drainage signals retained focus / wrong organism / resistance (IDSA/PIDS 2021)

cbc_with_differential*lab • INITIAL_WORKUP

WBC > 12,000 /µL is a Kocher predictor; baseline for trend; leukocytosis with left shift supports infection (Kocher 1999 PMID 10608376)

neuro_deficit_or_spinal_red_flags*symptom • RED_FLAGS

New motor/sensory deficit, saddle anaesthesia, bladder/bowel dysfunction with back pain + fever → vertebral osteomyelitis with epidural abscess / cord compression — neurosurgical emergency; do NOT delay antibiotics for biopsy when neuro deficit / sepsis (Berbari IDSA 2015)

creatinine_and_renal_function*lab • TREATMENT

Baseline + serial for vancomycin AUC-targeted dosing + nephrotoxicity monitoring, aminoglycoside avoidance, and antibiotic renal dose adjustment (IDSA 2020 vancomycin consensus PMID 32191793; FDA labels)

bone_or_operative_culturelab • BRANCHING_WORKUP

Image-guided or open bone biopsy / deep operative cultures (≥ 3-5 samples) — sinus-tract swabs are unreliable; vertebral-osteo biopsy yield falls after empiric antibiotics → hold antibiotics for biopsy if stable (Berbari IDSA 2015; ESCMID/EBJIS 2024)

kingella_pcr_or_blood_culture_bottle_inoculationlab • BRANCHING_WORKUP

In children < 4 yr (6-48 mo) inoculate synovial fluid / bone aspirate into blood-culture bottles + Kingella / 16S PCR — Kingella kingae is fastidious and culture-negative on standard plates; intrinsically resistant to vancomycin + clindamycin (IDSA/PIDS 2021; Yagupsky review)

mri_target_regionimaging • BRANCHING_WORKUP

not present

MRI is the imaging modality of choice for osteomyelitis (marrow oedema, abscess, sequestrum) and vertebral osteomyelitis (disc/endplate destruction, paravertebral/epidural abscess); sensitivity ~ 90-100 % (Berbari IDSA 2015; IDSA/PIDS 2021)

sexual_history_for_gonococcalhistory • CONTEXT

not present

Sexually active adolescent/adult with migratory polyarthralgia + tenosynovitis + pustular dermatitis OR purulent monoarthritis → disseminated gonococcal infection; ceftriaxone + chlamydia co-treatment + partner notification (CDC STI; IDSA)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (10)

10 need judgement

informationallife_threateningneonatal_pseudoparalysis
Pseudoparalysis / reluctance to move a limb in a neonate or young infant — septic arthritis or osteomyelitis until proven otherwise; often MULTIFOCAL; pathogens GBS + S. aureus + Gram-negative (E. coli); STAT imaging + aspiration + broad empirics + multifocal survey + urgent paediatric-orthopaedics (IDSA/PIDS 2021)
Trigger could not be auto-evaluated — needs clinician judgement.
informationallife_threateningbji_with_bacteremia_or_septic_shock
Bone & joint infection with positive blood cultures OR sepsis / septic-shock criteria — cross-route id.sepsis.core.v1 (SSC Hour-1 bundle) with carryover (organism + source-control status + antibiotic stack); source control within 6-12 h is an independent mortality determinant (SSC 2026; IDSA/PIDS 2021)
Trigger could not be auto-evaluated — needs clinician judgement.
informationallife_threateningvertebral_osteomyelitis_with_neuro_deficit_or_epidural_abscess
Vertebral osteomyelitis / discitis with new motor/sensory deficit, saddle anaesthesia, bladder/bowel dysfunction, OR an epidural abscess on MRI — neurosurgical emergency; do NOT delay empiric antibiotics for biopsy when neuro deficit / sepsis present; emergent decompression (Berbari IDSA 2015)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseverenative_septic_arthritis_emergency
Acute monoarthritis + fever with synovial WBC > 50,000 /µL PMN-predominant OR positive Gram stain — native septic arthritis is a closed-space orthopaedic EMERGENCY; cartilage destruction begins within hours; STAT arthrocentesis (before antibiotics) + empiric vancomycin + ceftriaxone/cefepime + urgent joint drainage (Margaretten JAMA 2007 PMID 17405973; IDSA septic arthritis)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalsevereseptic_hip_or_shoulder_surgical_drainage
Paediatric septic hip (Kocher 3-4/4: fever > 38.5 °C, non-weight-bearing, ESR > 40, WBC > 12,000 ± CRP > 20 mg/L) OR septic shoulder — these joints are NOT reliably decompressed by needle aspiration → US-guided aspiration + urgent arthrotomy or arthroscopic washout + empiric cefazolin (Kingella-active) ± vancomycin (Kocher 1999 PMID 10608376; Caird 2006 PMID 16757758; IDSA/PIDS 2021)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseveremrsa_risk_empiric_vancomycin
BJI with MRSA risk (prior MRSA, healthcare exposure, IVDU, high local prevalence, prosthetic joint, severe sepsis) — empiric vancomycin (AUC-targeted) until MSSA confirmed; NARROW to cefazolin or nafcillin once MSSA confirmed (β-lactam superior to vancomycin for MSSA) (IDSA MRSA; IDSA 2020 vancomycin consensus PMID 32191793)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseveresickle_cell_salmonella_or_pseudomonas_ivdu
Sickle-cell disease (multifocal long-bone osteomyelitis → cover Salmonella + S. aureus; distinguish from bone infarction) OR IVDU / plantar puncture through shoe (axial / sternoclavicular / sacroiliac joint or osteochondritis → add anti-pseudomonal) — host-pathogen-specific empiric broadening (classic teaching pearls)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalsevereprosthetic_joint_infection_source_control
Prosthetic-joint infection — source-control strategy: DAIR (debridement + antibiotics + implant retention) for a well-fixed implant + < 3 wk symptom duration + susceptible organism + exchangeable modular liner; otherwise one-stage or two-stage exchange (chronic, sinus tract, difficult organism, loose implant). Staphylococcal PJI with retained hardware → RIFAMPIN combination (always with a companion agent — never monotherapy) (Osmon IDSA PJI 2013; Zimmerli; ESCMID/EBJIS 2024)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalmoderatekingella_age_shift_under_4yr
Child < 4 yr (especially 6-48 mo) with osteoarticular infection — Kingella kingae is the LEADING pathogen in this band; often indolent with mild inflammatory markers; intrinsically resistant to vancomycin + clindamycin → retain a β-lactam (cefazolin/ceftriaxone); inoculate synovial/bone aspirate into blood-culture bottles + send Kingella / 16S PCR (IDSA/PIDS 2021; Yagupsky review)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalmoderatedisseminated_gonococcal_infection
Sexually active adolescent/adult with migratory polyarthralgia + tenosynovitis + pustular dermatitis triad OR purulent monoarthritis — disseminated gonococcal infection; ceftriaxone + empiric chlamydia co-treatment + partner notification + STI screen; characteristic rapid clinical response (CDC STI; IDSA)
Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

BJI empiric (vancomycin + ceftriaxone/cefepime, age + host stratified) → culture-directed narrowing (MSSA → cefazolin/nafcillin; Kingella β-lactam; gonococcal ceftriaxone; Salmonella; Pseudomonas anti-pseudomonal; PJI rifampin combination) + source control (joint drainage / debridement / DAIR vs exchange) + IV-to-oral early switch (OVIVA Li NEJM 2019)

axis: bji_empiric_targeted_and_source_controlstep empiric_vancomycin_plus_third_or_fourth_gen_cephalosporin - Empiric vancomycin + ceftriaxone (default) OR + cefepime (Pseudomonas risk: IVDU / plantar puncture)

Selected step "Empiric vancomycin + ceftriaxone (default) OR + cefepime (Pseudomonas risk: IVDU / plantar puncture)" — Suspected native septic arthritis / acute osteomyelitis / Kocher-positive paediatric septic hip after cultures obtained (or sepsis — without delay)

vancomycin
first line
glycopeptide
Adult: 25-30 mg/kg IV load × 1 → 15-20 mg/kg q8-12 h targeting AUC24 400-600; Peds: 15 mg/kg IV q6 h (AUC-titrated) • IV • load then q6-12 h (AUC-titrated)
triggers: mrsa_risk, empiric_septic_arthritis, empiric_osteomyelitis
MRSA + most streptococcal cover; AUC-targeted not trough (IDSA 2020 vancomycin consensus PMID 32191793); narrow to a β-lactam once MSSA confirmed
rxcui 11124
ceftriaxone
first line
third_gen_cephalosporin
Adult: 2 g IV q24h; Peds: 50-100 mg/kg/day IV • IV • q24h
triggers: empiric_gram_negative_cover, gonococcal_risk, salmonella_sickle_cell, kingella_under_4yr
Gram-negative + gonococcal + Salmonella cover; Kingella-active β-lactam in children < 4 yr (Kingella intrinsically vancomycin/clindamycin-resistant) (IDSA/PIDS 2021)
rxcui 2193
cefepime
comorbidity specific
fourth_gen_cephalosporin
Adult: 2 g IV q8h; Peds: 50 mg/kg/dose IV q8h • IV • q8h
triggers: pseudomonas_risk_ivdu, plantar_puncture_through_shoe, healthcare_associated
Anti-pseudomonal cover for IVDU / plantar-puncture phenotype + healthcare-associated; renal adjust for CrCl < 60 (IDSA septic arthritis)
rxcui 20481

outpatient playbook — drug actions (3)

1. oral continuation per OVIVA / Peltola
High-bioavailability oral agent per susceptibility for the remainder of the course • PO • per agent
trigger: Source controlled + susceptible + responding + reliable absorption
Oral non-inferior to IV for first 6 wk of complex BJI (OVIVA Li NEJM 2019 PMID 30699315); paediatric short-course (Peltola / IDSA-PIDS 2021)
2. OPAT parenteral agent (when IV required for duration)
Per organism + susceptibility via OPAT • IV (OPAT) • per agent
trigger: Organism / susceptibility / source-control status mandates a parenteral agent
OPAT for the parenteral-required tail of therapy with line + drug-level surveillance
3. chronic oral suppression (PJI retention strategies)
Per organism (often a β-lactam or fluoroquinolone ± rifampin companion) for prolonged suppression • PO • per agent
trigger: PJI managed by DAIR / implant retention
Prolonged oral suppression in retention strategies per Osmon IDSA PJI 2013; arthroplasty-team follow-up

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Acute monoarthritis (warm, swollen, painful joint, restricted ROM) + fever — septic arthritis until proven otherwise; STAT arthrocentesis (Margaretten JAMA 2007 PMID 17405973; IDSA septic arthritis); Refusal to bear weight / limp / atraumatic hip pain in a child — apply Kocher predictors (fever > 38.5 °C, non-weight-bearing, ESR > 40, WBC > 12,000) ± CRP > 20 mg/L to distinguish septic hip vs transient synovitis (Kocher 1999 PMID 10608376; Caird 2006 PMID 16757758); Pseudoparalysis / reluctance to move a limb in a neonate / young infant — septic arthritis or osteomyelitis until proven otherwise; often multifocal; GBS + S. aureus + Gram-negative; STAT imaging + aspiration (IDSA/PIDS 2021).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute Osteomyelitis & Septic Arthritis** (id.osteomyelitis-septic-arthritis.v1).
Phenotype framing: Septic arthritis vs crystal arthropathy (gout/CPPD — crystal microscopy pivot; crystals + infection can co-exist) vs reactive/post-infectious arthritis (sterile culture + antecedent GI/GU infection + HLA-B27) vs rheumatoid/inflammatory flare; septic hip vs transient synovitis in children (Kocher predictor count + CRP > 20 mg/L pivot — transient synovitis afebrile, weight-bearing-tolerant, low markers, self-limited); osteomyelitis vs bone infarction in sickle-cell (MRI + aspiration pivot) vs Charcot neuroarthropathy in diabetic foot (probe-to-bone + biopsy pivot); vertebral osteomyelitis vs metastatic disease / compression fracture (disc-space + endplate destruction + paravertebral abscess favour infection); PJI vs aseptic loosening (ESR/CRP, synovial PJI thresholds, alpha-defensin, ≥ 2 deep cultures, sinus tract); S. aureus vertebral osteo ↔ infective endocarditis (persistent bacteraemia + new murmur + TEE — bidirectional) (Margaretten JAMA 2007 PMID 17405973; Berbari IDSA 2015)
Scope: Bone & joint infection spectrum: acute osteomyelitis (hematogenous — peds metaphyseal AHO + adult vertebral osteomyelitis/discitis; contiguous — post-trauma/surgical/diabetic-foot/decubitus/dental; direct-inoculation — open fracture/plantar puncture) + native septic arthritis (closed-space orthopaedic EMERGENCY — cartilage destruction within hours) + prosthetic-joint infection (biofilm-mediated) × acute (< 2 wk, no sequestrum) vs subacute/chronic (sequestrum, involucrum, sinus tract, Brodie abscess) × pathogen-host band (S. aureus incl MRSA default; Kingella < 4 yr; GBS neonate; gonococcal sexually active; Salmonella sickle-cell; Pseudomonas IVDU/plantar-puncture; Streptococcus) (Berbari IDSA 2015; IDSA/PIDS 2021; Osmon IDSA PJI 2013)

No severity triggers fired against current inputs.

Plan

Regimen axis: **BJI empiric (vancomycin + ceftriaxone/cefepime, age + host stratified) → culture-directed narrowing (MSSA → cefazolin/nafcillin; Kingella β-lactam; gonococcal ceftriaxone; Salmonella; Pseudomonas anti-pseudomonal; PJI rifampin combination) + source control (joint drainage / debridement / DAIR vs exchange) + IV-to-oral early switch (OVIVA Li NEJM 2019)** — step "Empiric vancomycin + ceftriaxone (default) OR + cefepime (Pseudomonas risk: IVDU / plantar puncture)".
1. vancomycin Adult: 25-30 mg/kg IV load × 1 → 15-20 mg/kg q8-12 h targeting AUC24 400-600; Peds: 15 mg/kg IV q6 h (AUC-titrated) IV load then q6-12 h (AUC-titrated) (glycopeptide, first line) — MRSA + most streptococcal cover; AUC-targeted not trough (IDSA 2020 vancomycin consensus PMID 32191793); narrow to a β-lactam once MSSA confirmed
2. ceftriaxone Adult: 2 g IV q24h; Peds: 50-100 mg/kg/day IV IV q24h (third_gen_cephalosporin, first line) — Gram-negative + gonococcal + Salmonella cover; Kingella-active β-lactam in children < 4 yr (Kingella intrinsically vancomycin/clindamycin-resistant) (IDSA/PIDS 2021)
3. cefepime Adult: 2 g IV q8h; Peds: 50 mg/kg/dose IV q8h IV q8h (fourth_gen_cephalosporin, comorbidity specific) — Anti-pseudomonal cover for IVDU / plantar-puncture phenotype + healthcare-associated; renal adjust for CrCl < 60 (IDSA septic arthritis)

Setting playbook (outpatient) — Oral continuation per OVIVA / Peltola (or OPAT if IV required), CRP/ESR surveillance to normalisation, orthopaedic + ID follow-up, functional rehabilitation, relapse / chronic-osteomyelitis return precautions, seeding-source resolution (OVIVA Li NEJM 2019 PMID 30699315; Berbari IDSA 2015)
4. oral continuation per OVIVA / Peltola High-bioavailability oral agent per susceptibility for the remainder of the course PO per agent — Source controlled + susceptible + responding + reliable absorption (Oral non-inferior to IV for first 6 wk of complex BJI (OVIVA Li NEJM 2019 PMID 30699315); paediatric short-course (Peltola / IDSA-PIDS 2021))
5. OPAT parenteral agent (when IV required for duration) Per organism + susceptibility via OPAT IV (OPAT) per agent — Organism / susceptibility / source-control status mandates a parenteral agent (OPAT for the parenteral-required tail of therapy with line + drug-level surveillance)
6. chronic oral suppression (PJI retention strategies) Per organism (often a β-lactam or fluoroquinolone ± rifampin companion) for prolonged suppression PO per agent — PJI managed by DAIR / implant retention (Prolonged oral suppression in retention strategies per Osmon IDSA PJI 2013; arthroplasty-team follow-up)

Non-pharmacologic actions:
- Physical / occupational therapy — progressive weight-bearing + joint ROM + functional recovery
- Orthopaedic + ID outpatient follow-up; arthroplasty-team follow-up for PJI
- Diabetic-foot offloading + glycaemic optimisation if contiguous diabetic-foot osteo (cross-reference endo.diabetes-related-foot-disease.v1)
- Address seeding source — endocarditis / line / dental / skin
- Patient education — relapse return precautions (recurrent pain, swelling, sinus drainage, fever), adherence importance

AVOID / contraindication checks:
- Vancomycin AUC target not trough (IDSA 2020 vancomycin consensus — AUC/MIC 400 600; PMID 32191793)
- Vancomycin nephrotoxicity monitor renal and levels (FDA label)
- Narrow to cefazolin or nafcillin once MSSA confirmed beta lactam superior to vancomycin (IDSA)
- Kingella intrinsically resistant to vancomycin and clindamycin retain beta lactam under 4yr (IDSA/PIDS 2021; Yagupsky review)
- Hold empiric antibiotics for vertebral osteo biopsy unless septic or neuro deficit (Berbari IDSA 2015)
- Rifampin never monotherapy companion drug required to prevent resistance (Osmon IDSA PJI 2013; Zimmerli)
- Rifampin cyp3a4 potent inducer and hepatotoxicity and orange secretions (FDA label)
- Fluoroquinolone tendinopathy qt aortic aneurysm warning (FDA label)
- Linezolid serotonin syndrome and myelosuppression beyond 14d and lactic acidosis (FDA label)
- Daptomycin weekly cpk monitoring not for pulmonary source (FDA label)
- Septic arthritis mandatory joint drainage hip and shoulder and paediatric hip surgical (IDSA septic arthritis; IDSA/PIDS 2021)
- Source control within 6 12h independent mortality determinant if bacteremic (SSC 2026)
- Deep operative cultures not sinus tract swabs for chronic osteomyelitis (ESCMID/EBJIS 2024)
- Iv to oral early switch non inferior once source controlled and susceptible (OVIVA Li NEJM 2019 PMID 30699315)

Monitoring

Regimen monitoring:
- CRP/ESR trajectory — CRP is the workhorse (falls faster than ESR); failure to fall ~ 50 % by day 3-5 despite adequate drainage → retained focus / wrong organism / resistance → repeat imaging + surgical re-look (IDSA/PIDS 2021)
- Clinical exam — joint ROM, pain, weight-bearing/pseudoparalysis resolution, wound/sinus drainage
- Blood-culture clearance if bacteraemic; S. aureus bacteraemia → TEE for endocarditis (cross-route id.endocarditis.core.v1)
- Vancomycin AUC + serial creatinine (nephrotoxicity; IDSA 2020 consensus PMID 32191793)
- Rifampin — LFTs + comprehensive drug-interaction review (potent CYP3A4 inducer); orange secretions counsel
- Linezolid — CBC weekly if > 14 d (myelosuppression) + serotonin-syndrome screen (avoid with serotonergic agents)
- Daptomycin — weekly CPK
- Fluoroquinolone — tendinopathy / QT / aortic counsel
- Paediatric — CRP-guided IV-to-oral switch + total-duration decision (short-course per Peltola / IDSA-PIDS 2021)
- Duration tracking: septic arthritis 2-4 wk; osteomyelitis 3-6 wk; native vertebral osteomyelitis ≥ 6 wk (Berbari IDSA 2015); PJI 6 wk IV-active backbone + prolonged oral suppression in retention

Setting (outpatient) monitoring:
- CRP/ESR surveillance until normalised
- Clinical + functional recovery trajectory
- Oral-regimen adherence + tolerability + drug-specific labs
- OPAT line + drug-level monitoring if applicable
- Relapse surveillance — chronic osteomyelitis can recur months-years later

Follow-up plan: Orthopaedic + ID follow-up; CRP/ESR surveillance until normalised; functional rehabilitation (joint ROM, weight-bearing progression); relapse / chronic-osteomyelitis return precautions (recurrent pain, swelling, sinus drainage, fever); vertebral osteo — follow-up MRI only if clinical failure (not routine; Berbari IDSA 2015); PJI — chronic oral suppression audit in retention strategies + arthroplasty-team follow-up; address seeding source (endocarditis if S. aureus bacteraemia; line if CRBSI; diabetic-foot offloading + glycaemic control)
- Close-out criterion: Follow-up + rehabilitation + relapse-precaution plan delivered; seeding source addressed

Monitoring phase: CRP/ESR trajectory (CRP is the workhorse — failure to fall by ~ 50 % by day 3-5 despite adequate drainage → retained focus / wrong organism / resistance → repeat imaging + surgical re-look); clinical exam (joint ROM, pain, weight-bearing, wound/sinus); blood cultures clearance if bacteraemic; vancomycin AUC + creatinine (nephrotoxicity); rifampin LFTs + drug-interaction review (potent CYP3A4 inducer); linezolid CBC if > 14 d (myelosuppression) + serotonin-syndrome screen; daptomycin CPK weekly; fluoroquinolone tendinopathy/QT counsel; paediatric — CRP-guided IV-to-oral switch + total-duration decision (IDSA/PIDS 2021)

Disposition

Current setting: outpatient — Oral continuation per OVIVA / Peltola (or OPAT if IV required), CRP/ESR surveillance to normalisation, orthopaedic + ID follow-up, functional rehabilitation, relapse / chronic-osteomyelitis return precautions, seeding-source resolution (OVIVA Li NEJM 2019 PMID 30699315; Berbari IDSA 2015)

Disposition criteria:
- Resolution: course completed + CRP/ESR normalised + functional recovery + no relapse features + seeding source addressed — discharge from BJI-specific surveillance (PJI retention: indefinite arthroplasty-team follow-up)

Escalation triggers (move to higher acuity):
- Recurrent pain / swelling / sinus drainage / fever → urgent ortho-ID review + re-image + cultures (relapse / chronic osteomyelitis)
- New systemic features / sepsis → ED + cross-route id.sepsis.core.v1
- Oral-regimen failure / intolerance → switch agent / OPAT / ID review
- PJI suppression failure → arthroplasty-team review for revision

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Pseudoparalysis / reluctance to move a limb in a neonate or young infant — septic arthritis or osteomyelitis until proven otherwise; often MULTIFOCAL; pathogens GBS + S. aureus + Gram-negative (E. coli); STAT imaging + aspiration + broad empirics + multifocal survey + urgent paediatric-orthopaedics (IDSA/PIDS 2021)
- [LIFE_THREATENING] Bone & joint infection with positive blood cultures OR sepsis / septic-shock criteria — cross-route id.sepsis.core.v1 (SSC Hour-1 bundle) with carryover (organism + source-control status + antibiotic stack); source control within 6-12 h is an independent mortality determinant (SSC 2026; IDSA/PIDS 2021)
- [LIFE_THREATENING] Vertebral osteomyelitis / discitis with new motor/sensory deficit, saddle anaesthesia, bladder/bowel dysfunction, OR an epidural abscess on MRI — neurosurgical emergency; do NOT delay empiric antibiotics for biopsy when neuro deficit / sepsis present; emergent decompression (Berbari IDSA 2015)

Citations

- IDSA Native Vertebral Osteomyelitis Guideline (Berbari CID 2015) + IDSA Septic Arthritis (native joint) standards + ACR acute monoarthritis approach + IDSA/PIDS Pediatric Acute Hematogenous Osteomyelitis Clinical Practice Guideline 2021 (Woods et al. — Kingella kingae age-shift, short-course IV-to-oral, MRI-first, CRP-guided duration) + IDSA Prosthetic Joint Infection Guideline (Osmon CID 2013 — DAIR vs 1-/2-stage exchange + rifampin combination for staphylococcal PJI with retained hardware) + ESCMID/EBJIS 2024 bone-and-joint-infection guidance + OVIVA (Li NEJM 2019 — oral vs IV antibiotic non-inferiority for complex BJI; failure 13.2 % oral vs 14.6 % IV) + Peltola pediatric short-course IV-to-oral RCTs + Margaretten JAMA 2007 (synovial-fluid rational clinical examination — synovial WBC LRs) + Kocher J Bone Joint Surg 1999 (paediatric septic-hip prediction rule) + Caird J Bone Joint Surg 2006 (CRP modification of Kocher) + Yagupsky Kingella kingae review + Zimmerli prosthetic-joint-infection review [PMID:30699315](https://pubmed.ncbi.nlm.nih.gov/30699315/)
- Cited evidence (PMID 17405973) [PMID:17405973](https://pubmed.ncbi.nlm.nih.gov/17405973/)
- Cited evidence (PMID 10608376) [PMID:10608376](https://pubmed.ncbi.nlm.nih.gov/10608376/)
- Cited evidence (PMID 16757758) [PMID:16757758](https://pubmed.ncbi.nlm.nih.gov/16757758/)
- Cited evidence (PMID 32191793) [PMID:32191793](https://pubmed.ncbi.nlm.nih.gov/32191793/)

Last reconciled with current guidelines: 2026-05-22.

References

IDSA Native Vertebral Osteomyelitis Guideline (Berbari CID 2015) + IDSA Septic Arthritis (native joint) standards + ACR acute monoarthritis approach + IDSA/PIDS Pediatric Acute Hematogenous Osteomyelitis Clinical Practice Guideline 2021 (Woods et al. — Kingella kingae age-shift, short-course IV-to-oral, MRI-first, CRP-guided duration) + IDSA Prosthetic Joint Infection Guideline (Osmon CID 2013 — DAIR vs 1-/2-stage exchange + rifampin combination for staphylococcal PJI with retained hardware) + ESCMID/EBJIS 2024 bone-and-joint-infection guidance + OVIVA (Li NEJM 2019 — oral vs IV antibiotic non-inferiority for complex BJI; failure 13.2 % oral vs 14.6 % IV) + Peltola pediatric short-course IV-to-oral RCTs + Margaretten JAMA 2007 (synovial-fluid rational clinical examination — synovial WBC LRs) + Kocher J Bone Joint Surg 1999 (paediatric septic-hip prediction rule) + Caird J Bone Joint Surg 2006 (CRP modification of Kocher) + Yagupsky Kingella kingae review + Zimmerli prosthetic-joint-infection review — PMID:30699315
Cited evidence (PMID 17405973) — PMID:17405973
Cited evidence (PMID 10608376) — PMID:10608376
Cited evidence (PMID 16757758) — PMID:16757758
Cited evidence (PMID 32191793) — PMID:32191793